Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Short-term Investments (2018 - 2019)

Apyx Medical filings provide 6 years of Short-term Investments readings, the most recent being $40.9 million for Q1 2019.

  • On a quarterly basis, Short-term Investments changed N/A to $40.9 million in Q1 2019 year-over-year; TTM through Mar 2019 was $40.9 million, a N/A change, with the full-year FY2018 number at $61.7 million, changed N/A from a year prior.
  • Short-term Investments hit $40.9 million in Q1 2019 for Apyx Medical, down from $61.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $61.7 million in Q4 2018 to a low of $172000.0 in Q3 2015.
  • Median Short-term Investments over the past 3 years was $20.6 million (2015), compared with a mean of $26.5 million.
  • The widest YoY moves for Short-term Investments: up 23.89% in 2015, down 23.89% in 2015.
  • Apyx Medical's Short-term Investments stood at $172000.0 in 2015, then surged by 35759.3% to $61.7 million in 2018, then plummeted by 33.71% to $40.9 million in 2019.
  • The last three reported values for Short-term Investments were $40.9 million (Q1 2019), $61.7 million (Q4 2018), and $55.5 million (Q3 2018) per Business Quant data.